ClinicalTrials.gg

POINT Biopharma clinical trials

Acquired by Eli Lilly and Company, Dec 26, 2023 · source ↗

The registry lists 2 studies whose lead sponsor is POINT Biopharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 13, 2026.

Before and after it joined Eli Lilly and Company

First submitted before POINT Biopharma became part of Eli Lilly and Company
2
First submitted after POINT Biopharma became part of Eli Lilly and Company
0
Unclear, or no submission date
0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

What it is testing

The drugs POINT Biopharma’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.

Studies, none open

All 2 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Under way, not recruiting150%
  • Stopped early150%

Phase

  • Phase 31
  • Phase 11

Where

  • Canada2
  • United States2
  • United Kingdom1
  • France1
  • Sweden1
  • Netherlands1

Over the years

  1. 121
  2. 22
  3. 23
  4. 24
  5. 25
  6. 026

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

  • POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company2 studies

Something wrong with this grouping? Tell us on the Eli Lilly and Company page.

Studies

Recruiting first, then most recently updated. Showing 2 of 2. All Eli Lilly and Company studies →